Department of Obstetrics and Gynecology, Rikshospitalet, Oslo University Hospital / Oslo and Akershus University College of Applied Sciences, Oslo, Norway.
Norwegian National Advisory Unit on Women's Health, Oslo, Norway.
BMC Pregnancy Childbirth. 2018 Mar 27;18(1):76. doi: 10.1186/s12884-018-1706-4.
The use of synthetic oxytocin for augmentation of labor is rapidly increasing worldwide. Hyper-stimulation is the most significant side effect, which may cause fetal distress and operative delivery. We performed an intervention consisting of an educational program and modified guidelines to achieve a more appropriate use of oxytocin.
This prospective intervention study included 431 first-time mothers at term with spontaneous onset of labor before (October 2012 to May 2013), and 664 after the intervention (April 2014 to April 2015). Our outcomes were prevalence and duration of oxytocin treatment, mode of delivery, indication for operative delivery, episiotomy, anal sphincter tears, bleeding, labor duration, pain relief and the effect of oxytocin on mode of delivery.
After the intervention, 52.9% were diagnosed with dystocia, compared with 68.9% before (p < 0.001). Oxytocin was not always used in accordance with the guidelines, but a significant reduction in oxytocin rates from 63.3% to 54.1% (p < 0.001) was obtained. More women without dystocia according to the existing guidelines were augmented after the intervention (18.9% vs 8.4%, p < 0.001). Assessing all labors, the median duration of oxytocin treatment was reduced by 72% (from 90 to 25 min) without increasing the median duration of labor (385 min in both groups). There was a moderate reduction in operative vaginal deliveries from 26.9 to 21.5% (p = 0.04), and dystocia as an indication for these deliveries increased (p = 0.01). There was a moderate increase in caesarean sections from 6.7 to 10.2% (p = 0.05), but no increase in dystocia as an indication for these deliveries. Women receiving oxytocin were more likely to have an operative vaginal birth, even after adjusting for birth weight, epidural analgesia and labor duration, OR: 2.1 (CI 1.1-4.0) before and OR 2.7 (CI 1.6-4.5) after the intervention.
Our intervention led to a significant reduction in the use of oxytocin. However, more than half of the women remained diagnosed with dystocia. Operative vaginal births seem to be associated with oxytocin treatment. Therefore, augmentation with oxytocin should be used with caution and only when medically indicated. Even more modified guidelines for augmentation than the ones applied in this study might be appropriate.
合成催产素在全世界范围内被广泛用于引产。过度刺激是最显著的副作用,可能导致胎儿窘迫和需要剖宫产。我们实施了一项干预措施,包括教育计划和修改后的指导方针,以实现更合理地使用催产素。
本前瞻性干预研究纳入了 431 例足月、自然临产的初产妇,其中干预前(2012 年 10 月至 2013 年 5 月)为 431 例,干预后(2014 年 4 月至 2015 年 4 月)为 664 例。我们的结局指标包括催产素治疗的发生率和持续时间、分娩方式、剖宫产指征、会阴切开术、肛门括约肌撕裂、出血、产程时间、疼痛缓解以及催产素对分娩方式的影响。
干预后,52.9%的产妇被诊断为产程异常,而干预前为 68.9%(p<0.001)。催产素的使用并不总是符合指南,但催产素使用率从 63.3%显著降至 54.1%(p<0.001)。干预后,更多根据现有指南无产程异常的产妇接受了催产素治疗(18.9% vs 8.4%,p<0.001)。评估所有产程,催产素治疗的中位时间减少了 72%(从 90 分钟降至 25 分钟),而总产程的中位时间无变化(两组均为 385 分钟)。阴道助产分娩率从 26.9%降至 21.5%(p=0.04),这些分娩的剖宫产指征增加(p=0.01)。剖宫产率从 6.7%适度增加至 10.2%(p=0.05),但这些分娩的剖宫产指征无增加。接受催产素的产妇更有可能行阴道助产分娩,即使调整了出生体重、硬膜外镇痛和产程时间,OR:干预前为 2.1(95%CI 1.1-4.0),干预后为 2.7(95%CI 1.6-4.5)。
我们的干预措施显著减少了催产素的使用。然而,仍有一半以上的产妇被诊断为产程异常。阴道助产分娩似乎与催产素治疗有关。因此,应谨慎使用催产素引产,仅在医学指征下使用。甚至比本研究中应用的指导方针更严格的催产素引产指导方针可能更合适。